NASDAQ:SRGA Surgalign - SRGA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Surgalign Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.12 +0.08 (+3.92%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.87▼$2.1950-Day Range$1.36▼$2.7952-Week Range$1.34▼$21.45Volume79,373 shsAverage Volume60,787 shsMarket Capitalization$14.32 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Surgalign MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,315.1% Upside$30.00 Price TargetShort InterestHealthy1.91% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.66) to ($0.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 starsMedical Sector728th out of 1,055 stocksSurgical Appliances & Supplies Industry15th out of 24 stocks 3.5 Analyst's Opinion Consensus RatingSurgalign has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.00, Surgalign has a forecasted upside of 1,315.1% from its current price of $2.12.Amount of Analyst CoverageSurgalign has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.91% of the float of Surgalign has been sold short.Short Interest Ratio / Days to CoverSurgalign has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Surgalign has recently increased by 15.93%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSurgalign does not currently pay a dividend.Dividend GrowthSurgalign does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SRGA. Previous Next 1.9 News and Social Media Coverage News SentimentSurgalign has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Surgalign this week, compared to 2 articles on an average week.Search Interest5 people have searched for SRGA on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Surgalign to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Surgalign insiders have not sold or bought any company stock.Percentage Held by Insiders10.30% of the stock of Surgalign is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.78% of the stock of Surgalign is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Surgalign are expected to grow in the coming year, from ($3.66) to ($0.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Surgalign is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Surgalign is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSurgalign has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Surgalign (NASDAQ:SRGA) StockSurgalign Holdings, Inc. is a medical technology company, which engages in designing, developing, and manufacturing biologic metal and synthetic implants. Its products portfolio include cervical fixation, The Streamline (TL) fixation, motion preservation, orthobiologics, cervical inter-body fusion, TL IBF, and SI joint fusion. It offers coflex interlaminar stabilization device, SImmetry sacroiliac joint fusion system, and Fortilink IBF system with TETRAfuse?3D technology. The company was founded on February 12, 1998 and is headquartered in Deerfield, IL.Read More Receive SRGA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surgalign and its competitors with MarketBeat's FREE daily newsletter. Email Address SRGA Stock News HeadlinesDecember 28, 2022 | finance.yahoo.comSurgalign Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation SystemDecember 15, 2022 | finance.yahoo.comSurgalign Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation SystemJanuary 27, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 13, 2022 | finance.yahoo.comSurgalign™ Expands Adoption of its HOLO Portal™ Surgical Guidance System in VirginiaNovember 16, 2022 | finance.yahoo.comSurgalign Announces Closing of $12.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNovember 14, 2022 | finance.yahoo.comSurgalign Announces $12.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNovember 9, 2022 | finance.yahoo.comSurgalign™ Announces Corporate Restructuring Program to Focus on Key Growth AreasNovember 4, 2022 | seekingalpha.comSurgalign Holdings, Inc. (SRGA) Q3 2022 Earnings Call TranscriptJanuary 27, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…November 4, 2022 | msn.comHow Is The Market Feeling About Surgalign Holdings?November 2, 2022 | finance.yahoo.comSurgalign Announces Third Quarter 2022 Results and Provides Update on Business Operations and Financial OutlookOctober 30, 2022 | fool.comSurgalign Holdings, Inc. (NASDAQ: SRGA)October 25, 2022 | finance.yahoo.comSurgalign Schedules Third Quarter 2022 Earnings Release for November 2, 2022October 11, 2022 | globenewswire.comSurgalign™ Awarded 2022 Best New Technology Award from Orthopedics This Week for its HOLO Portal™ Surgical Guidance System - GlobeNewswireOctober 11, 2022 | finance.yahoo.comSurgalign™ Awarded 2022 Best New Technology Award from Orthopedics This Week for its HOLO Portal™ Surgical Guidance SystemOctober 4, 2022 | globenewswire.comRapid Prototyping Materials Market to cross $1.3 Bn by 2030, says Global Market Insights Inc. - GlobeNewswireSeptember 26, 2022 | globenewswire.comSurgalign Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures - GlobeNewswireSeptember 26, 2022 | finance.yahoo.comSurgalign Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion ProceduresSeptember 15, 2022 | globenewswire.comSurgalign Announces Third Clinical Site in the Commercialization of its HOLO Portal™ Surgical Guidance System - GlobeNewswireSeptember 15, 2022 | benzinga.comSurgalign Holdings (NASDAQ:SRGA) – Surgalign Announces Third Clinical Site in the Commercialization of it - BenzingaSeptember 15, 2022 | finance.yahoo.comSurgalign Announces Third Clinical Site in the Commercialization of its HOLO Portal™ Surgical Guidance SystemSeptember 8, 2022 | globenewswire.comSurgalign to Exhibit at the Society for Minimally Invasive Spine Surgery (“SMISS”) Annual Forum and the North American Spine Society (“NASS”) 2022 Annual Meeting - GlobeNewswireSeptember 8, 2022 | finance.yahoo.comSurgalign to Exhibit at the Society for Minimally Invasive Spine Surgery (“SMISS”) Annual Forum and the North American Spine Society (“NASS”) 2022 Annual MeetingAugust 24, 2022 | benzinga.comSurgalign Gets FDA 510(k) Clearance For Spinal Fixation SystemAugust 24, 2022 | finance.yahoo.comSurgalign Scores FDA Approval For New Flagship Posterior Fixation PlatformAugust 24, 2022 | globenewswire.comSurgalign Announces FDA 510(k) Clearance of the Cortera™ Spinal Fixation System – The Company's New Flagship Posterior Fixation Platform - GlobeNewswireAugust 24, 2022 | finance.yahoo.comSurgalign Announces FDA 510(k) Clearance of the Cortera™ Spinal Fixation System – The Company’s New Flagship Posterior Fixation PlatformSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SRGA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surgalign and its competitors with MarketBeat's FREE daily newsletter. Email Address SRGA Company Calendar Last Earnings11/02/2022Today1/27/2023Next Earnings (Estimated)3/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRGA CUSIPN/A CIK1760173 Webwww.surgalign.com Phone(224) 303-4651Fax386-418-0342Employees231Year FoundedN/APrice Target and Rating Average Stock Price Forecast$30.00 High Stock Price Forecast$30.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+1,315.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($12.2299) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-84,650,000.00 Net Margins-73.11% Pretax Margin-124.83% Return on Equity-343.08% Return on Assets-52.45% Debt Debt-to-Equity Ratio0.82 Current Ratio1.92 Quick Ratio1.27 Sales & Book Value Annual Sales$90.50 million Price / Sales0.16 Cash FlowN/A Price / Cash FlowN/A Book Value$1.69 per share Price / Book1.25Miscellaneous Outstanding Shares6,756,000Free Float6,060,000Market Cap$14.32 million OptionableOptionable Beta1.76 Key ExecutivesTerry M. RichPresident, Chief Executive Officer & DirectorDavid B. LyleChief Financial OfficerG. Bryan CornwallExecutive VP-Research & Clinical AffairsBob WatkinsChief Technology OfficerKris SiemionowChief Medical OfficerKey CompetitorsSientraNASDAQ:SIENNanoVibronixNASDAQ:NAOVEargoNASDAQ:EARInvacareNYSE:IVCConformisNASDAQ:CFMSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 19,906 shares on 11/15/2022Ownership: 2.631%Koss Olinger Consulting LLCBought 10,460 shares on 11/15/2022Ownership: 0.155%Renaissance Technologies LLCSold 35,875 shares on 11/14/2022Ownership: 0.869%David LyleBought 19,000 shares on 5/18/2022Total: $99,940.00 ($5.26/share)Terry M RichBought 434,784 shares on 2/15/2022Total: $200,000.64 ($0.46/share)View All Insider TransactionsView All Institutional Transactions SRGA Stock - Frequently Asked Questions Should I buy or sell Surgalign stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surgalign in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SRGA shares. View SRGA analyst ratings or view top-rated stocks. What is Surgalign's stock price forecast for 2023? 1 Wall Street research analysts have issued 1-year price objectives for Surgalign's shares. Their SRGA share price forecasts range from $30.00 to $30.00. On average, they anticipate the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 1,315.1% from the stock's current price. View analysts price targets for SRGA or view top-rated stocks among Wall Street analysts. How have SRGA shares performed in 2023? Surgalign's stock was trading at $1.99 on January 1st, 2023. Since then, SRGA shares have increased by 6.5% and is now trading at $2.12. View the best growth stocks for 2023 here. Are investors shorting Surgalign? Surgalign saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 110,600 shares, an increase of 15.9% from the December 31st total of 95,400 shares. Based on an average daily volume of 73,700 shares, the short-interest ratio is presently 1.5 days. Currently, 1.9% of the company's shares are short sold. View Surgalign's Short Interest. When is Surgalign's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023. View our SRGA earnings forecast. How were Surgalign's earnings last quarter? Surgalign Holdings, Inc. (NASDAQ:SRGA) posted its earnings results on Wednesday, November, 2nd. The company reported ($1.96) earnings per share for the quarter. The firm had revenue of $20.18 million for the quarter. Surgalign had a negative net margin of 73.11% and a negative trailing twelve-month return on equity of 343.08%. When did Surgalign's stock split? Shares of Surgalign reverse split before market open on Tuesday, May 17th 2022. The 1-30 reverse split was announced on Tuesday, May 17th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 17th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What guidance has Surgalign issued on next quarter's earnings? Surgalign updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $82.00 million-$84.00 million, compared to the consensus revenue estimate of $85.96 million. What is Surgalign's stock symbol? Surgalign trades on the NASDAQ under the ticker symbol "SRGA." How do I buy shares of Surgalign? Shares of SRGA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Surgalign's stock price today? One share of SRGA stock can currently be purchased for approximately $2.12. How much money does Surgalign make? Surgalign (NASDAQ:SRGA) has a market capitalization of $14.32 million and generates $90.50 million in revenue each year. The company earns $-84,650,000.00 in net income (profit) each year or ($12.2299) on an earnings per share basis. How many employees does Surgalign have? The company employs 231 workers across the globe. How can I contact Surgalign? Surgalign's mailing address is 520 LAKE COOK ROAD SUITE 315, DEERFIELD IL, 60015. The official website for the company is www.surgalign.com. The company can be reached via phone at (224) 303-4651, via email at info@surgalign.com, or via fax at 386-418-0342. This page (NASDAQ:SRGA) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.